Axon Laboratories Profile
Key Indicators
- Authorised Capital ₹ 6.00 M
as on 21-12-2024
- Paid Up Capital ₹ 4.00 M
as on 21-12-2024
- Company Age 27 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 9.70 M
as on 21-12-2024
- Satisfied Charges ₹ 4.50 M
as on 21-12-2024
- Revenue 12.13%
(FY 2022)
- Profit -87.24%
(FY 2022)
- Ebitda -57.75%
(FY 2022)
- Net Worth 4.32%
(FY 2022)
- Total Assets 88.07%
(FY 2022)
About Axon Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 6.00 M and a paid-up capital of Rs 4.00 M.
The company currently has active open charges totaling ₹9.70 M. The company has closed loans amounting to ₹4.50 M, as per Ministry of Corporate Affairs (MCA) records.
Tanya Sood and Somanshu Sood serve as directors at the Company.
- CIN/LLPIN
U24230PB1997PTC019447
- Company No.
019447
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Feb 1997
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Hoshiarpur, Punjab, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Axon Laboratories?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Somanshu Sood  | Managing Director | 23-Sep-2020 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Tanya Sood | Director | 31-Jan-2021 | Current |
Financial Performance of Axon Laboratories.
Axon Laboratories Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 12.13% increase. The company also saw a substantial fall in profitability, with a 87.24% decrease in profit. The company's net worth moved up by a moderate rise of 4.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Axon Laboratories?
In 2022, Axon Laboratories had a promoter holding of 10.75% and a public holding of 89.25%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 13 May 2024 | ₹0.65 M | Open |
Others Creation Date: 27 Mar 2024 | ₹5.00 M | Open |
Oriental Bank Of Commerce Creation Date: 19 Jun 2000 | ₹0.55 M | Open |
How Many Employees Work at Axon Laboratories?
Unlock and access historical data on people associated with Axon Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Axon Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Axon Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
